VPC-18005 是一种荧光素酶抑制剂。 VPC-18005 抑制 ERG 诱导的转录并直接与 ERG-ETS 结构域相互作用，从而破坏 ERG 与 DNA 的结合。

VPC-18005 is a luciferase inhibitor. VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain thereby disrupting the ERG binding to DNA.

VPC-18005 (1 and 10 μM) produced a 20–30% decrease in the dissemination of cancer cells in zebrafsh[1]. VPC-18005 (5 μM) inhibits pETS-luc reporter activity with IC50s of 3 and 6 μM in PNT1B-ERG and VCaP cells, respectively. VPC-18005 antagonizes the metastatic potential of ERG-expressing prostate cells and suppresses ERG reporter activity without exhibiting overt cytotoxicity. VPC-18005 inhibits migration and invasion of ERG-overexpressing cells in vitro[2].

2242480-48-2

C15H17N3O3S

319.38

VPC-18005

DMSO:60 mg/mL (187.86 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years